ALPN News and Press, Alpine Immune Sciences Inc. From 04/05/22

- AACR Investor Event time change to 6:30 p.m. ET - - 21st Annual Needham Virtual Healthcare Conference Presentation April 13 th at 1:30 p.m. ET - Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a leading clinical-stage immunotherapy company focused on developing inno...

- Novel approach to CD28 to enhance activation of T cells and anti-tumor activity - - Crystallography demonstrates critical interaction between davoceticept’s CD80 domain and PD-L1 - - Data further encourage ongoing davoceticept development, including NEON-1 mon...

- Alpine to hold Investor Event on Tuesday, April 12 th at 6:00pm ET - Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today annou...

Alpine Immune Sciences press release (NASDAQ:ALPN): Q4 GAAP EPS of -$0.52 misses by $0.22. Revenue of $4.53M (-19.7% Y/Y) misses by $9.44M. For further details see: Alpine Immune Sciences GAAP EPS of -$0.52 misses by $0.22, revenue of $4.53M misses by $9.44M

- Execution across three clinical-stage programs and addition of $176 million in committed cash in 2021 from partnerships and financing to further advance pipeline - - Davoceticept monotherapy dose escalation data to be presented at 2022 AACR Annual Meeting - - ALPN-30...

- NEON-1 Data Selected for Minisymposium Oral Presentation - Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the accep...

Gainers: Clover Health Investments (NASDAQ:CLOV) +18%. Monte Rosa Therapeutics (NASDAQ:GLUE) +12%. Sharecare (NASDAQ:SHCR) +10%. InflaRx (NASDAQ:IFRX) +9%. Sigilon Therapeutics (NASDAQ:SGTX) +9%. Losers: Atreca (NASDAQ:BCEL) -30%. Biophytis (NASDAQ:BPTS) -14%. Alpine Immun...

The FDA has placed a partial clinical hold on a phase 2 trial of Alpine Immune Sciences' (NASDAQ:ALPN) davoceticept for advanced malignancies following a patient death. The company said the participant had received a single dose each of davoceticept and Keytruda (pembrolizumab). The caus...

-NEON-1 Study of ALPN-202 as a Monotherapy is Unaffected- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that the U.S...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that members of its management team will participate at the following investor con...